Exact Mass: 639.289076

Exact Mass Matches: 639.289076

Found 71 metabolites which its exact mass value is equals to given mass value 639.289076, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Protorifamycin I

Protorifamycin I

C35H45NO10 (639.304331)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins

   

34a-Deoxyrifamycin W

34a-Deoxy-rifamycin W

C35H45NO10 (639.304331)


   
   
   

5-O-Dimethoxytrityl-N-isobutyryl-deoxyguanosine

5-O-Dimethoxytrityl-N-isobutyryl-deoxyguanosine

C35H37N5O7 (639.2692852)


   

Hexosyl LPE 18:2

Hexosyl LPE 18:2

C29H54NO12P (639.3383454)


Annotation level-3

   
   
   
   
   
   

N2-iBu-DMT- dG

Guanosine, 5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-N-(2-methyl-1-oxopropyl)-

C35H37N5O7 (639.2692852)


relative retention time with respect to 9-anthracene Carboxylic Acid is 1.363 5'-O-DMT-N2-ibu-dG (N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyguanosine) is a deoxynucleoside which can be used in the preparation of oligonucleotides[1].

   

EETVY

Glu Glu Thr Val Tyr

C28H41N5O12 (639.2751586)


   

EKYSN

Glu Lys Tyr Ser Asn

C27H41N7O11 (639.2863916)


   

FLVMM

Phe-Leu-Val-Met-Met

C30H49N5O6S2 (639.3124094000001)


   

HLDQQ

His Leu Asp Gln Gln

C26H41N9O10 (639.2976246000001)


   

GalNAcβ1-4[Fucα1-3]GlcNAcβ-Sp

GalNAcβ1-4[Fucα1-3]GlcNAcβ-Sp

C24H41N5O15 (639.2599036)


   

Leukotriene C4 methyl ester

5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-eicosatetraenoic acid, methyl ester

C31H49N3O9S (639.3189344000001)


   

N-methyl Leukotriene C4

N-methyl-5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-eicosatetraenoic acid

C31H49N3O9S (639.3189344000001)


   

Am-Hex-LPE 18:2

N-(1-deoxyfructosyl)-1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine

C29H54NO12P (639.3383454)


   

Abivertinib maleate

Abivertinib maleate

C30H34FN7O8 (639.2452776)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Cyclooctaselenium

Cyclooctaselenium

Se8 (639.332168)


   

5-O-Dimethoxytrityl-benzoyl-2-deoxyguanosine

5-O-Dimethoxytrityl-benzoyl-2-deoxyguanosine

C35H37N5O7 (639.2692852)


   

Chaxamycin A

Chaxamycin A

C35H45NO10 (639.304331)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins

   

34a-Deoxy-rifamycin W

34a-Deoxy-rifamycin W

C35H45NO10 (639.304331)


   

25-O-deacetyl-27-O-demethylrifamycin S

25-O-deacetyl-27-O-demethylrifamycin S

C34H41NO11 (639.2679476000001)


   

(5Z,9alpha,13E,15S)-9-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-11-oxoprosta-5,13-dien-1-oate

(5Z,9alpha,13E,15S)-9-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-11-oxoprosta-5,13-dien-1-oate

C30H45N3O10S-2 (639.282551)


   

(5Z,11alpha,13E,15S)-11-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-9-oxoprosta-5,13-dien-1-oate

(5Z,11alpha,13E,15S)-11-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-9-oxoprosta-5,13-dien-1-oate

C30H45N3O10S-2 (639.282551)


   

(5Z,11beta,13E,15S)-11-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-9-oxoprosta-5,13-dien-1-oate

(5Z,11beta,13E,15S)-11-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-9-oxoprosta-5,13-dien-1-oate

C30H45N3O10S-2 (639.282551)


   

(5Z,9beta,13E,15S)-9-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-11-oxoprosta-5,13-dien-1-oate

(5Z,9beta,13E,15S)-9-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-11-oxoprosta-5,13-dien-1-oate

C30H45N3O10S-2 (639.282551)


   

(5S,6R,7E,9E,14Z)-6-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-5-hydroxy-12-oxoicosa-7,9,14-trienoate

(5S,6R,7E,9E,14Z)-6-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-5-hydroxy-12-oxoicosa-7,9,14-trienoate

C30H45N3O10S-2 (639.282551)


   

(6Z,8Z,10S,11S,12R,13R,14S,15R,16S,17S,19Z)-11,13,15,17,22-pentahydroxy-18-(hydroxymethyl)-6,10,12,14,16,20,23-heptamethyl-11,12,13,14,15,16,17,18-octahydro-1H-3,25-methano-4-benzazacyclotricosine-1,5,21,26(4H,10H)-tetrone

(6Z,8Z,10S,11S,12R,13R,14S,15R,16S,17S,19Z)-11,13,15,17,22-pentahydroxy-18-(hydroxymethyl)-6,10,12,14,16,20,23-heptamethyl-11,12,13,14,15,16,17,18-octahydro-1H-3,25-methano-4-benzazacyclotricosine-1,5,21,26(4H,10H)-tetrone

C35H45NO10 (639.304331)


   
   
   
   
   
   
   
   

2-amino-3-[[3-butanoyloxy-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-butanoyloxy-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C32H50NO10P (639.317217)


   

[1-hydroxy-3-[hydroxy-[2-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]ethoxy]phosphoryl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[2-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]ethoxy]phosphoryl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C29H54NO12P (639.3383454)


   

[2-hydroxy-3-[hydroxy-[2-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]ethoxy]phosphoryl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

[2-hydroxy-3-[hydroxy-[2-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]ethoxy]phosphoryl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

C29H54NO12P (639.3383454)


   

(2S)-2-amino-3-[[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C32H50NO10P (639.317217)


   

(2S)-2-amino-3-[[3-[(E)-dec-4-enoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[3-[(E)-dec-4-enoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C32H50NO10P (639.317217)


   

Chaxamycin A, rel-

Chaxamycin A, rel-

C35H45NO10 (639.304331)


A natural product found in Streptomyces speciesC34.

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

DTP3 (TFA)

DTP3 (TFA)

C28H36F3N7O7 (639.2628182000001)


DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].

   

4-hydroxy-n-{11-hydroxy-9-isopropyl-13-methyl-2,8,15,22-tetraoxo-14-oxa-1,7,10,21-tetraazatetracyclo[21.4.0.0³,⁷.0¹⁶,²¹]heptacos-10-en-12-yl}benzamide

4-hydroxy-n-{11-hydroxy-9-isopropyl-13-methyl-2,8,15,22-tetraoxo-14-oxa-1,7,10,21-tetraazatetracyclo[21.4.0.0³,⁷.0¹⁶,²¹]heptacos-10-en-12-yl}benzamide

C33H45N5O8 (639.326797)